Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker RXRX
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Catherine D. Wood | 44.75M | 8.4% | SCHEDULE 13G/A ↗ |
| Nov 13, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | ARK Investment Management LLC | 44.75M | 8.4% | SCHEDULE 13G/A ↗ |
| Nov 10, 2026 | SCHEDULE 13G | RXRX Recursion Pharmaceuticals, Inc. | State Street Corporation | 30.00M | 5.6% | SCHEDULE 13G ↗ |
| Aug 7, 2026 | SCHEDULE 13G | RXRX Recursion Pharmaceuticals, Inc. | State Street Corporation | 34.71M | 6.6% | SCHEDULE 13G ↗ |
| Jul 31, 2026 | SCHEDULE 13G | RXRX Recursion Pharmaceuticals, Inc. | Vanguard Portfolio Management | 31.37M | 6.0% | SCHEDULE 13G ↗ |
| Jul 31, 2026 | SCHEDULE 13G | RXRX Recursion Pharmaceuticals, Inc. | Vanguard Capital Management | 26.74M | 5.1% | SCHEDULE 13G ↗ |
| Jul 29, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | BlackRock, Inc. | 44.54M | 8.5% | SCHEDULE 13G/A ↗ |
| May 12, 2026 | SCHEDULE 13G | RXRX Recursion Pharmaceuticals, Inc. | State Street Corporation | 28.49M | 5.5% | SCHEDULE 13G ↗ |
| Apr 24, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | BlackRock, Inc. | 37.82M | 7.2% | SCHEDULE 13G/A ↗ |
| Mar 27, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | The Vanguard Group | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Feb 5, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Baillie Gifford & Co | 23.77M | 4.6% | SCHEDULE 13G/A ↗ |
| Feb 3, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Catherine D. Wood | 37.32M | 7.3% | SCHEDULE 13G/A ↗ |
| Feb 3, 2026 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | ARK Investment Management LLC | 37.32M | 7.3% | SCHEDULE 13G/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | MIC Capital Partners (Ventures) Europe Parallel (Luxembourg) Aggregator SCSp | 1.19M | 0.2% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | MC Alternative Solutions, LP | 1.39M | 0.3% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | MIC Capital Management UK LLP | 2.58M | 0.5% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | MDC Capital Partners (Ventures), LP | 7.06M | 1.4% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | MDC Capital Partners (Ventures) GP, LP | 7.06M | 1.4% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Mamoura Diversified Global Holding PJSC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Dec 23, 2025 | SCHEDULE 13D/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Mubadala Investment Co PJSC | 0 | 0.0% | SCHEDULE 13D/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | RA Capital Healthcare Fund, L.P. | 7.73M | 2.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Rajeev Shah | 7.73M | 2.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Peter Kolchinsky | 7.73M | 2.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | RA Capital Management, L.P. | 7.73M | 2.0% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | ARK Investment Management LLC | 32.35M | 8.5% | SCHEDULE 13G/A ↗ |
| Feb 12, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | Baillie Gifford & Co | 24.86M | 6.5% | SCHEDULE 13G/A ↗ |
| Feb 5, 2025 | SCHEDULE 13G/A (amended) | RXRX Recursion Pharmaceuticals, Inc. | BlackRock, Inc. | 23.44M | 6.1% | SCHEDULE 13G/A ↗ |
27 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 10:02 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances